{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"23"}]}],"title":"International response criteria (>= PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"32"}]}],"title":"clinical benefit response (>= minor response)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"Percent of participants with response according to international response criteria (\\>= PR) and percent of participants with clinical benefit response (\\>= minor response according to adapted EBMT criteria). Determined with serum and 24 hour urine protein electrophoresis, and as appropriate, supplemented by immunofixation, serum free light chain assay, and bone marrow examination. Response before high dose melphalan and autologous stem cell transplant will also be confirmed by two separate blood and 24 hour urine tests between the last dose of combination therapy and the first dose of the mobilizing agent.","groups":[{"description":"Participants receive azacitidine subcutaneously once or twice weekly and oral dexamethasone once weekly starting on day 1. Participants also receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses. Participants then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Overall Study - (Azacitidine/Lenalidomide/Dexamethasone)"},{"description":"Participants who received HTLD and HTLD-CKD dose: Azacitidine 50mg/m2 2x week + Lenalidomide 25mg (or 10mg for CKD) d1-21 every 28d + Dexamethasone 40mg once a week","id":"OG001","title":"Participants Who Received HTLD/HTLD-CKD"}],"paramType":"NUMBER","populationDescription":"Response-evaluable participants","reportingStatus":"POSTED","timeFrame":"at 12 months","title":"Percent of Participants With Clinical Benefit and Response According to International Response Criteria","type":"SECONDARY","unitOfMeasure":"percentage of participants"}